Environmental, Social and Governance Report 2025 環境、社會及管治報告 Table of Contents 目錄 | MESSAGE FROM THE BOARD | 董事會致辭 | 2 | | --- | --- | --- | | ABOUT BAIJIN LIFE SCIENCE | 關於佰金生命科學 | 3 | | ABOUT THE REPORT | 關於本報告 | 4 | | Reporting Scope and Period | 報告範圍及期間 | 4 | | Reporting Principle | 匯報原則 | 5 | | Report Access and feedback | 獲取報告及反饋 | 5 | | SUSTAINABILITY GOVERNANCE | 可持續發展管治 | 6 | | STAKEHOLDERS ENGAGEMENT | 持份者參與 | 6 | | MATERIALITY ASSESSMENT | 重要性評估 | 9 | | ENVIRONMENTAL ASPECTS | 環境層面 | 10 | | EMISSI ...

Baijin Life Science Holdings Limited (the "Company") — Notification of publication of Annual Report, Circular and Notice of Annual General Meeting (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communication are available on the Company's website at www.baijinlifescience.com and the website of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") at www.hkexnews.hk respectively (the "Website Version"). The Company strongly recommends you ...

佰金生命科學控股有限公司 佰 金 生 命 科 學 控 股 有 限 公 司 (Stock Code: 1466) (Incorporated in the Cayman Islands with limited liability) (Incorporated in Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） （Stock Code 股份代號：1466） NOTIFICATION LETTER 通知信函 Date as postmarked Baijin Life Science Holdings Limited Baijin Life Science Holdings Limited Actionable Corporate Communications refer to any corporate communications that seek instructions from the Shareholders on how they wish to exercise their rights or make elections as ...

（於開曼群島註冊成立之有限公司） （股份代號： 1466） Baijin Life Science Holdings Limited 佰金生命科學控股有限公司 2025年 股 東 週 年 大 會 之 代 表 委 任 表 格 本人╱吾等 (1) 地址為 為佰金生命科學控股有限公司（「本公司」）股本中每股面值0.02港元之股份共 股 (2) 之註冊持有人， 茲委任 (3) 本公司股東週年大會（「大會」）（或其任何續會）主席或 收 集 個 人 資 料 聲 明 閣 下 是 自 願 提 供 閣 下 及 閣 下 委 任 代 表 的 姓 名 及 地 址，以 用 於 處 理 就 本 公 司 大 會 有 關 閣 下 委 任 代 表 的 任 命 及 投 票 指 示（「該 等 用 途」）。我 們 可 能 向 就 該 等 用 途 為 本 公 司 提 供 行 政、電 腦 及 其 他 服 務 的 代 理 人、承 辦 商 或 第 三 者 服 務 供 應 商，以 及 其 他 獲 法 例 授 權 而 要 求 取 得 有 關 資 料 的 人 士 或 其 他 與 上 述 所 列 出 的 該 等 用 途 有 關 以 及 需 要 接 收 有 關 資 ...

閣 下 如 對 本 通 函 任 何 方 面 或 應 採 取 之 行 動 有 任 何 疑 問，應 諮 詢 閣 下 之 持 牌 證 券 交 易 商、銀 行 經 理、律 師、專 業 會 計 師 或 其 他 專 業 顧 問。 閣 下 如 已 將 名 下 之 佰 金 生 命 科 學 控 股 有 限 公 司 股 份 全 部 出 售 或 轉 讓，應 立 即 將 本 通 函 連 同 隨 附 之 代 表 委 任 表 格 送 交 買 主 或 承 讓 人 或 經 手 買 賣 或 轉 讓 之 銀 行、 持 牌 證 券 交 易 商 或 其 他 代 理 商，以 便 轉 交 買 主 或 承 讓 人。 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 通 函 之 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 通 函 全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 此 乃 要 件 請 即 處 理 Baijin Life Science Holdings Limited 佰金生命科學 ...

特 別 事 項 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 通 告 之 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 通 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Baijin Life Science Holdings Limited 佰金生命科學控股有限公司 （股份代號： 1466） （於開曼群島註冊成立之有限公司） 股 東 週 年 大 會 通 告 茲 通 告 佰 金 生 命 科 學 控 股 有 限 公 司（「本 公 司」）謹 訂 於2025年9月30日（星 期 二） 上 午 十 一 時 正 假 座 香 港 九 龍 灣 宏 照 道19號 金 利 豐 國 際 中 心8樓D室 舉 行2025年 股 東 週 年 大 會，藉 以 商 討 以 下 事 項： 普 通 事 項 – 1 – 1. 接 納 及 考 慮 本 公 司 截 至2025年3月31日 止 年 度 之 經 審 核 財 務 報 表、董 事 會 報 告 及 獨 立 核 數 師 報 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 佰金生命科學控股有限公司 第 1 頁 共 10 頁 v 1.1.1 FF301 FF301 II. 已發行股份及/或庫存股份變動 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01466 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.02 HKD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 之 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何 部 份 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 之 任 何 損 失 承 擔 任 何 責 任。 Baijin Life Science Holdings Limited 佰金生命科學控股有限公司 （股份代號： 1466） （於開曼群島註冊成立之有限公司） （前稱為錢唐控股有限公司） 截 至2025年3月31日 止 財 政 年 度 之 全 年 業 績 公 告 及 恢 復 買 賣 業 績 佰 金 生 命 科 學 控 股 有 限 公 司（「本 公 司」）董 事 會（「董 事」或「董 事 會」）謹 此 呈 列 本 公 司 及 其 附 屬 公 司（以 下 統 稱「本 集 團」）截 至2025年3月31日 止 年 度 之 綜 合 業 績，連 同 去 年 之 比 較 數 字 如 下： – 1 – 綜 合 損 益 表 截 至2025 ...

Core Viewpoint - Baijin Life Sciences (01466.HK) has announced a delay in the publication of its 2025 annual results due to a longer-than-expected handover process following changes in the management of its subsidiary [1] Group 1: Announcement Details - The company has stated that it has only recently gained full control over the operations of its subsidiary, which has contributed to the delay in the annual results [1] - The expected publication date for the 2025 annual results is set for July 25, 2025 [1] Group 2: Trading Suspension - According to Listing Rule 13.5, if the issuer fails to publish periodic financial information as required, the stock exchange typically requires a suspension of trading in the issuer's securities [1] - If the company does not announce the 2025 annual results by June 30, 2025, trading of its shares is expected to be suspended starting from 9:00 AM on July 2, 2025 [1]

Financial Performance - For the six months ended September 30, 2024, the company reported a profit before income tax of HK$706,000[19] - The Company reported a total comprehensive loss of HK$9,682 for the period, compared to a loss of HK$6,227 in the previous period, indicating an increase in losses of approximately 55.5%[41] - Revenue for the six months ended September 30, 2024, was HK$70,900,000, a significant increase from HK$25,121,000 in the same period of 2023, representing a growth of 182%[126] - Gross profit for the period was HK$16,805,000, compared to HK$3,617,000 in the previous year, indicating a substantial improvement[126] - The operating profit for the period was HK$794,000, a recovery from an operating loss in the previous year[126] - Loss for the period decreased to HK$1,901,000 from HK$2,318,000 year-over-year, showing a reduction in losses[127] - Total comprehensive expense for the period was HK$5,356,000, compared to HK$3,079,000 in the prior year, reflecting increased expenses[127] Assets and Liabilities - Total assets as of September 30, 2024, amounted to HK$147,717,000, an increase from HK$121,320,000 as of March 2024[15] - Current liabilities were reported at HK$73,885,000, with trade and other payables amounting to HK$53,159,000[15] - Total liabilities stood at HK$129,259,000, with unallocated corporate liabilities at HK$59,379,000[90] - As of September 30, 2024, total assets amounted to HK$196,802, with unallocated goodwill at HK$48,363 and unallocated corporate assets at HK$25,520[55] - The total liabilities of the Company as of September 30, 2024, were HK$84,010, with unallocated corporate liabilities at HK$53,443[55] - Non-current liabilities increased significantly to HK$55,374,000 as of September 30, 2024, up from HK$43,016,000 as of March 31, 2024[129] - Net assets decreased to HK$107,436,000 from HK$112,792,000, indicating a decline in overall asset value[129] Cash Flow - The company experienced a net cash used in operating activities of HK$8,392,000 for the six months ended September 30, 2024[19] - The group reported a net cash generated from investing activities of HK$230,000, a decrease from HK$690,000 in the previous year[112] - Net cash generated from financing activities increased significantly to HK$18,000,000 compared to HK$371,000 in the prior period[112] - Cash and cash equivalents stood at HK$44,370,000 as of September 30, 2024[15] - Cash and cash equivalents at the end of the period were HK$44,370,000, up from HK$41,231,000 year-over-year[112] Segment Performance - Segment revenue from pearl and fine jewellery products was HK$70,151, while skincare business revenue was HK$3,598, and research and solutions development services generated HK$16,114, contributing to a total segment revenue of HK$122,919[55] - The skincare solutions business segment generated a profit of HK$7,204,000, while the sales of pearls and fine jewellery products reported a loss of HK$2,078,000[86] - The total segment profit for the group was HK$5,088,000, indicating a positive performance overall despite some segments reporting losses[86] - The skincare solutions segment's revenue was HK$15,156,000, while research and solutions development services reported revenue of HK$849,000[86] - The strategic investment and financial services segment did not report any revenue during this period[86] - Segment revenue for the six months ended September 30, 2024, totaled HK$70,900,000, with the sales of pearls and fine jewellery products contributing HK$50,417,000[86] Corporate Governance and Compliance - The interim financial statements have been prepared in accordance with Hong Kong Accounting Standards, ensuring compliance with local regulations[24] - The Company has complied with all code provisions as set out in the Corporate Governance Code throughout the six months ended 30 September 2024, except for the separation of the roles of chairman and chief executive officer[144] - The Company has adopted a corporate governance statement of policy to guide the application of corporate governance principles[144] - The condensed consolidated financial statements have not been audited but have been reviewed by the Company's audit committee[59] - The Audit Committee comprises three independent non-executive Directors who have recommended the adoption of the interim results to the Board[199] Shareholder and Equity Information - For the six months ended September 30, 2024, the total equity attributable to equity holders of the Company decreased to HK$86,626, down from HK$96,308 as of April 1, 2024, representing a decline of approximately 10.5%[41] - The Company has no controlling shareholder, with Pacific Wish Limited being the substantial shareholder[45] - The Company was listed on the Main Board of The Stock Exchange of Hong Kong Limited on October 17, 2014[45] - The Group's share capital as of 30 September 2024 was HK$200,000, with 10,000,000 ordinary shares authorized at HK$0.02 each[183] - The Company issued 39,954,338 new shares at an issue price of HK$0.2628 to satisfy the aggregate consideration for the acquisition of Tonnett Group[165] Strategic Focus and Development - The company is focused on expanding its skincare solutions through self-developed brands and high-end functional skincare products[23] - The company is engaged in strategic investments and financial services, enhancing its operational capabilities[23] - The company is focused on expanding its strategic investment and financial services segment, aiming for growth in this area[114] - The company is actively pursuing new product development and market expansion strategies to enhance its competitive position[114] - The group currently operates five segments following the acquisition of Tonnett Julis Holdings Limited on February 9, 2024[81] Other Financial Information - The Company has adopted new and amended HKFRSs effective from April 1, 2024, but these changes had no material impact on the financial performance for the current and prior periods[51] - The financial statements have been prepared on a historical cost basis, except for certain financial instruments measured at fair values[47] - Interest received decreased to HK$609,000 from HK$690,000 in the previous year, indicating a potential area for improvement[112] - Interest expenses on borrowings increased to HK$289,000 in the six months ended 30 September 2024, compared to HK$87,000 in the same period in 2023[167] - Key management compensation for the six months ended 30 September 2024 was HK$2,374,000, a decrease from HK$5,946,000 in the same period in 2023[168] - The Group incurred rental expenses of HK$180,000 for the office property rented from a related party during the six months ended 30 September 2024, consistent with the previous year[171] - The landlord of the rented property is a wholly owned subsidiary of Far East Holdings International Limited, which is listed on the Main Board of the Stock Exchange[172] - The Group's related party transactions were conducted based on mutually agreed terms[171] - There were no purchases, sales, or redemptions of the Company's listed securities for the six months ended 30 September 2024[198] - The Group's segment performance monitoring allocates all liabilities to operating segments, excluding certain financial instruments and borrowings[187] - The changes in director's information were disclosed in accordance with Rule 13.51B(1) of the Listing Rules, with no other information required to be disclosed[197] - The group has not completed the initial allocation of goodwill from a business combination, which will be finalized in the current financial year[91] - No options were lapsed, granted, exercised, or cancelled under the New Share Option Scheme during the reporting period[142] - The new share option scheme will be valid for ten years and includes performance targets for options to vest[138] - The maximum number of shares that may be issued upon exercise of Options yet to be granted under the New Share Option Scheme is 67,925,226, representing approximately 10% of the total number of shares in issue of the Company (i.e. 679,252,266 ordinary shares)[142]